Advances in crystallography and protein spectroscopy have accelerated the discovery of active sites or "binding pockets" within specific biologic targets. These advances, combined with structure-based drug design, have allowed biotechs to develop highly specific small-molecule inhibitors with far less guesswork, and in turn far smaller budgets.
Blood cancers depend on the dysregulation of key cellular pathways and processes. Improved understanding of those processes and pathways has resulted in an unprecedented number of drugs specifically designed to target them. At the recently concluded American Society of Clinical Oncology (OTC:ASCO) 2013 meeting, investigators presented dozens of studies concerning 11 new drugs developed to combat B-cell malignancies. All 11 were designed to specifically target one of five different proteins involved in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|